Hansa Biopharma AB (HNSA.ST), a biopharmaceutical company, Thursday reported a wider net loss for the third quarter compared to last year. The results were impacted by reduced revenue, wider loss from operations and other expenses.
The quarterly loss was 148.3 million Swedish kroner, wider than 103.8 kroner in the earlier year.
Hansa Biopharma's revenue for the third quarter declined to 30.8 million kroner from 48.7 million kroner.
Renée Aguiar-Lucander, CEO of Hansa Biopharma said its Imlifidase has successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation during the third quarter. The company is targeting a Biologics License Application submission to the FDA under the accelerated approval pathway and intend to request a Priority Review.
On the Stockholm Stock Exchange, shares were trading 12.88 percent lower at 30.02 Swedish Kronor.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.